Macular Telangiectasia (MacTel, Type 2)
A bilateral condition involving abnormal, dilated capillaries and progressive degeneration of the retina around the macula, of unclear underlying cause. It typically affects adults in mid-to-later life.
.jpeg)
Symptoms
Gradual blurring of central vision
​
Difficulty reading, particularly missing letters or words
​
Mild metamorphopsia​​
​
Symptoms are often subtle early on and slowly progressive
Findings
Retinal graying and loss of transparency temporal to the fovea​
​Right-angle venules and telangiectatic capillaries
​Loss of outer retinal layers and cavitation on OCT
​
Late leakage on fluorescein angiography
​
Possible neovascularization in advanced cases
Treatments
ENCELTO (revakinagene taroretcel-lwey): an FDA-approved, surgically implanted encapsulated cell therapy that delivers ciliary neurotrophic factor (CNTF) to slow photoreceptor loss, for progressive MacTel cases
​
Observation and monitoring: for patients not pursuing implant therapy, ​
​Anti-VEGF injections: reserved for eyes that develop neovascularization
​
​​​
Low vision aids: for reading and near-vision support